This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Coxsackievirus Infections Treatment Market

Market Insights on Coxsackievirus Infections Treatment covering sales outlook, demand forecast & up-to-date key trends

Coxsackievirus Infections Treatment Market by Drug Type, by Route of Administration, by Distribution Channel, by Region | Forecast 2023 to 2033

Coxsackievirus Infections Treatment Market Snapshot (2023 to 2033)

The global coxsackievirus infections treatment market is currently valued at US$ 5.5 Billion in 2023 and is anticipated to expand at a CAGR of 8.2%. Owing to the technological advances in healthcare the market is likely to propel to US$ 12.1 Billion by 2033.

An increase in demand for improved healthcare infrastructure and an increasing incidence rate is likely to drive the growth of the coxsackievirus infections treatment market in the forecast period.

Report Attribute

Details

Expected Market Value (2023)

US$ 5.5 Billion

Projected Forecast Value (2033)

US$ 12.1 Billion

Global Growth Rate (2023 to 2033)

8.2% CAGR

Coxsackieviruses are non-enveloped viruses belonging to the picornaviridae family and enterovirus genus that possess linear single-stranded RNA as their genetic material. Based on their pathogenicity tested on mice, these are categorized into group A and group B viruses.

Group A viruses are known to cause skin and mucous membrane infections, leading to disorders such as herpangina, hand-foot-and-mouth (HFM) disease, and acute hemorrhagic conjunctivitis (AHC).

Group B viruses infect the pancreas, liver, and heart, leading to various conditions such as pericarditis, hepatitis, myocarditis, and pleurodynia. According to Centers for Disease Control and Prevention (CDC) estimates, coxsackievirus infections accounted for around 25% of the neonatal enterovirus infections reported from 1983 to 2003. People from all age groups get infected by coxsackievirus; however, children are more susceptible to the infection. Fetuses or newborns are at a high risk of infection if their mother gets infected during pregnancy. These viruses are found in the feces, fluid in blisters, nasal secretions, and saliva of an infected patients.

Customize this Report

Let us know your requirement to get
100% FREE customization

Which are Some Prominent Drivers of Coxsackievirus Infections Treatment Market?

Growing Incidences of Infections Cause by Coxsackievirus to Drive the Market Growth

Major factors driving the global coxsackievirus diagnostics market are an increase in the incidence of coxsackievirus infections, the surge in awareness among the people, and rigorous government initiatives to reduce the incidence of these infections.

Also, the increasing awareness regarding hand, foot, and mouth disease treatment among people, the availability of cost-effective drugs in the market, and the high prevalence of viral infection causing HFMD in children across the globe is expected to be the key factor driving the growth of coxsackievirus infections treatment market.

Increasing investments in research and development activities to drive the market growth

The global coxsackievirus infections treatment market is anticipated to observe impressive growth during the forecast period, 2023 to 2033. Extensive research and development are propelling the growth of the market, globally.

The other factors supporting the market’s growth are, the increasing government investments in research & development activities, the growing footprint of pharmaceutical manufacturers, developed healthcare infrastructure, rising awareness among the masses, and technological advancements.

Also, ease in FDA approvals for hand, foot, and mouth disease (HFMD) drugs in the clinical trial phase is further projected to drive the growth of the coxsackievirus infections treatment market. Owing to the large patient pool due to HFMD, the demand for coxsackievirus infections treatment is upsurging.

Which factors are limiting the growth of Coxsackievirus infections treatment market?

Lack of Awareness Regarding Coxsackievirus to Restrain the Market Growth

One of the major factors hindering the growth of the coxsackievirus infections treatment market over the analysis period includes the lack of awareness regarding the infection. The high cost of therapeutics is another factor that is expected to impede the market growth.

Lack of resources and accessibility in remote areas is one of the key factors likely to hamper the growth of the coxsackievirus infections treatment market. Moreover, the development of more sensitive, efficient, and yet simple rapid diagnostic systems that can be applied to direct and indirect diagnosis remains a challenge in the coxsackievirus infections treatment market.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Country-Wise Insights

What Makes USA an Attractive Market for Coxsackievirus Infections Treatment?

Advancement in Healthcare to Boost the Market Growth in Region

The market in the North American region is anticipated to observe vibrant growth during the forecast period 2023 to 2033. This can be attributed to the growing developments in the healthcare sector as a result of rising research and development activities in this industry. The region is expected to hold the highest CAGR of 8.0% during the forecast period.

North America led the market in terms of revenue due to the presence of several leading players in the region and various strategic initiatives undertaken by them. Moreover, various government initiatives to promote the diagnosis of various infectious diseases are likely to offer lucrative growth opportunities during the coming years.

For instance, in February 2012, CDC received reports of 63 persons with signs and symptoms of HFMD or with fever and atypical rash in Alabama (38 cases), California (seven), Connecticut (one), and Nevada (17). Coxsackievirus A6 (CVA6) was detected in 25 (74%) of those 34 patients by reverse transcriptase–polymerase chain reaction and partial sequencing of the VP1 gene at the CDC or at the California Department of Public Health.

What makes the Asia Pacific the Most Lucrative Market for Coxsackievirus Infections Treatment Market?

Increasing Prevalence of HFMD in The Region to Boost the Market Growth

The Asia Pacific's coxsackievirus infection treatment market is expected to rise at a CAGR of 7.9% from 2023 to 2033. Asia Pacific dominates the coxsackievirus infection treatment market owing to the high geriatric population and increasing disease burden in economies such as India, China, and South Korea.

Asia Pacific is projected to hold the largest shares in the global coxsackievirus infection treatment market primarily due to the growing prevalence of HFMD in children in the Asia Pacific region coupled with Asia Pacific being the most vulnerable area for a number of outbreaks of EV71 HFMD.

The growing healthcare industry and an aging population consequently would lead to an increased patient population in these countries. India, China, and Brazil are expected to be rapidly growing markets, owing to an increase in investments by governments in order to enhance healthcare facilities.

Country-wise Forecast CAGRs for the Coxsackievirus Infections Treatment Market

United Kingdom

8.0%

India

7.9%

South Korea

7.5%

China

7.6%

United States of America

8.1%

Category wise Insights

Based on Drug Type, Which Is the Most Prominent Segment in Coxsackievirus Infections Treatment Market?

Acetaminophen Segment to Generate Significantly High Revenue

On the basis of drug type coxsackievirus infection treatment market is classified into acetaminophen, paracetamol, and ibuprofen. Among these acetaminophen registers the highest demand in the coxsackievirus infections treatment market owing to the fewer side effects registered with the usage of this drug as compared to others. coxsackievirus infections treatment was found major used in the management of blisters in the mouth and rashes on hands and feet.

The rising prevalence of viral infections in children below age 10 and the growing economic burden caused by HFMD is one of the major factors driving the demand for coxsackievirus infections treatment drugs for the early management of viral infection in children, thereby fueling the market growth over the globe.  The Acetaminophen segment held a dominant market share in the year 2023 and is estimated to grow with the fastest CAGR rate of 8.0% over the forecast period 2022 to 2023.

By Distribution Channel, which segment generates high revenue in the Coxsackievirus Infections Treatment market?

Hospital Pharmacy Segment Remains Dominant Among Other Types  

The hospital pharmacy segment dominated the global market in 2023 with a revenue share of over 55.0%. The growth of the segment is attributed to the increasing prevalence of coxsackievirus infections and hospitalization for treatment.

Hospital pharmacies preserve the stock of products related to coxsackievirus infections for out-patients as well as in-patients. The segment will be driven further by growing consumer awareness and increased investments in healthcare infrastructure in developing and underdeveloped countries.

The online pharmacies segment is expected to be the fastest-growing distribution channel segment. This growth can be attributed to user-friendly interfaces and convenience offered by these pharmacies, in terms of access, prices, and delivery. In addition, they have several discounts on purchases of a certain amount or offer bundle pricing for many products.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

How do New Entrants Contribute to the Coxsackievirus Infections Treatment Market?

Start-up Scenario

With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the coxsackievirus infections treatment market.

Some of the start-ups in the coxsackievirus infections treatment market include-

  • Provention Bio is a clinical-stage biopharmaceutical company engaged in the sourcing, development, and commercialization of novel therapeutics to intercept and prevent immune-mediated diseases. Its products help in the treatment of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and proviral infections. The company's pipeline includes clinical assets licensed from Janssen (2 inflammatory bowel disease candidates, a small-molecule CSF-1R inhibitor JNJ-40346527 for Crohn's disease, and JNJ-42915925, an anti-TLR3 antibody,) and Vactech (Enterovirus vaccine platform to pre-empt type 1 diabetes by targeting Coxsackievirus B infection).
  • SingVax is focused on the development of prophylactic vaccines for infectious diseases. The company’s product candidates include the Enterovirus 71 vaccine for the prevention of hand, foot, and mouth disease in children; the Japanese Encephalitis (JE) vaccine for the prevention of JE virus infection; and the chikungunya virus vaccine. As of Oct 2009, SingVax was acquired by Inviragen.

Competitive Landscape

Some of the key players present in the global coxsackievirus infections treatment markets are Adimmune Corp., CJ HealthCare Corp., Takeda Pharmaceutical Co Ltd., Shanghai Zerun Biotechnology Co Ltd., Chongqing Zhifei Biological Products Co Ltd., Johnson & Johnson Consumer Inc., GlaxoSmithKline plc., Emergex Vaccines Holdings Ltd, CJ HealthCare Corp., Thermo Fisher Scientific Inc., and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, applications, and industries.

  • In January 2023, Thermo Fisher Scientific Inc. announced that it has completed its acquisition of The Binding Site Group a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital.
  • In October 2022, Emergex Vaccines Holding Limited a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces that it has acquired the assets of Zosano Pharma Corporation.
  • In December 2022, Johnson & Johnson, the world’s largest, most diversified healthcare products company, announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment.

Report Scope

Report Attribute

Details

Growth Rate

CAGR 8.2% from 2023 to 2033

Expected Market Value (2023)

US$ 5.5 Billion

Projected Forecast Value (2033)

US$ 12.1 Billion

Base Year for Estimation

2022

Historical Data

2018 to 2022

Forecast Period

2023 to 2033

Quantitative Units

Revenue in USD Billion & CAGR from 2023 to 2033

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends & Pricing Analysis

Segments Covered

  • Drug Type
  • Route of Administration
  • Distribution Channel
  • Regions

Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa (MEA)

Key Countries Profiled

  • United States of America
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Australia
  • New Zealand
  • China
  • Japan
  • South Korea
  • GCC Countries
  • South Africa
  • Israel

Key Companies Profiled

  • Adimmune Corp.
  • CJ HealthCare Corp.
  • Takeda Pharmaceutical Co Ltd.
  • Shanghai Zerun Biotechnology Co Ltd.
  • Chongqing Zhifei Biological Products Co Ltd.
  • Johnson & Johnson Consumer Inc.
  • GlaxoSmithKline plc.
  • Emergex Vaccines Holdings Ltd
  • CJ HealthCare Corp.
  • Thermo Fisher Scientific Inc.

Customization

Available Upon Request

Key Segments Covered in the Coxsackievirus Infections Treatment Market Industry Survey

Coxsackievirus Infections Treatment Market by Drug Type:

  • Acetaminophen
  • Ibuprofen
  • Anti-inflammatory
  • Nucleoside Analogue Antivirals
  • Others

Coxsackievirus Infections Treatment Market by Route of Administration:

  • Topical
  • Oral
  • Intravenous

Coxsackievirus Infections Treatment Market by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Coxsackievirus Infections Treatment Market by Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

The global coxsackievirus infections treatment market is likely to reach a valuation of US$ 5.5 Billion by the end of 2023.

Adimmune Corp., CJ HealthCare Corp., Takeda Pharmaceutical Co Ltd., Shanghai Zerun Biotechnology Co Ltd. are some of the key players in the global coxsackievirus infections treatment market.

Sales of the coxsackievirus infections treatment market are likely to expand at 8.2% CAGR through 2033.

The US, Canada, Japan, China, & Germany are expected to drive most of the demand for the coxsackievirus infections treatment market.

By the end of 2033, the global market for coxsackievirus infections treatment market is predicted to reach a valuation of US$ 12.1 Billion.

Table of Content

1. Executive Summary | Coxsackievirus Infections Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033

        5.3.1. Acetaminophen

        5.3.2. Ibuprofen

        5.3.3. Anti-inflammatory

        5.3.4. Nucleoside Analogue Antivirals

        5.3.5. Others

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033

6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Topical

        6.3.2. Oral

        6.3.3. Intravenous

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. Middle East & Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Drug Type

        9.2.3. By Route of Administration

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Type

        9.3.3. By Route of Administration

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Type

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Type

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. South Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Drug Type

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Drug Type

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Oceania Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Drug Type

        14.2.3. By Route of Administration

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Type

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Drug Type

        15.2.3. By Route of Administration

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Type

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Drug Type

            16.1.2.2. By Route of Administration

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Drug Type

            16.2.2.2. By Route of Administration

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Drug Type

            16.3.2.2. By Route of Administration

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Drug Type

            16.4.2.2. By Route of Administration

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Drug Type

            16.5.2.2. By Route of Administration

            16.5.2.3. By Distribution Channel

    16.6. UK

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Drug Type

            16.6.2.2. By Route of Administration

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Drug Type

            16.7.2.2. By Route of Administration

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Drug Type

            16.8.2.2. By Route of Administration

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Drug Type

            16.9.2.2. By Route of Administration

            16.9.2.3. By Distribution Channel

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Drug Type

            16.10.2.2. By Route of Administration

            16.10.2.3. By Distribution Channel

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Drug Type

            16.11.2.2. By Route of Administration

            16.11.2.3. By Distribution Channel

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Drug Type

            16.12.2.2. By Route of Administration

            16.12.2.3. By Distribution Channel

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Drug Type

            16.13.2.2. By Route of Administration

            16.13.2.3. By Distribution Channel

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Drug Type

            16.14.2.2. By Route of Administration

            16.14.2.3. By Distribution Channel

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Drug Type

            16.15.2.2. By Route of Administration

            16.15.2.3. By Distribution Channel

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Drug Type

            16.16.2.2. By Route of Administration

            16.16.2.3. By Distribution Channel

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Drug Type

            16.17.2.2. By Route of Administration

            16.17.2.3. By Distribution Channel

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Drug Type

            16.18.2.2. By Route of Administration

            16.18.2.3. By Distribution Channel

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Drug Type

            16.19.2.2. By Route of Administration

            16.19.2.3. By Distribution Channel

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Drug Type

            16.20.2.2. By Route of Administration

            16.20.2.3. By Distribution Channel

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Drug Type

            16.21.2.2. By Route of Administration

            16.21.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Type

        17.3.3. By Route of Administration

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Adimmune Corp.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. CJ HealthCare Corp.

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Takeda Pharmaceutical Co Ltd.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Shanghai Zerun Biotechnology Co Ltd.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Chongqing Zhifei Biological Products Co Ltd.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Johnson & Johnson Consumer Inc.

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. GlaxoSmithKline plc.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Emergex Vaccines Holdings Ltd

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. CJ HealthCare Corp.

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Thermo Fisher Scientific Inc.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 3: Global Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 4: Global Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 5: North America Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 7: North America Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 8: North America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 9: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 11: Latin America Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 12: Latin America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 13: Europe Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 15: Europe Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 16: Europe Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 17: South Asia Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: South Asia Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 19: South Asia Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 20: South Asia Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 21: East Asia Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: East Asia Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 23: East Asia Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 24: East Asia Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 25: Oceania Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: Oceania Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 27: Oceania Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 28: Oceania Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 29: MEA Value (US$ Million) Forecast by Country, 2018 to 2033

Table 30: MEA Value (US$ Million) Forecast by Drug Type, 2018 to 2033

Table 31: MEA Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 32: MEA Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Value (US$ Million) by Drug Type, 2023 to 2033

Figure 2: Global Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 3: Global Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 4: Global Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 9: Global Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 10: Global Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 11: Global Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 12: Global Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 13: Global Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 14: Global Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 15: Global Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 16: Global Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 17: Global Attractiveness by Drug Type, 2023 to 2033

Figure 18: Global Attractiveness by Route of Administration, 2023 to 2033

Figure 19: Global Attractiveness by Distribution Channel, 2023 to 2033

Figure 20: Global Attractiveness by Region, 2023 to 2033

Figure 21: North America Value (US$ Million) by Drug Type, 2023 to 2033

Figure 22: North America Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 23: North America Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 24: North America Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 29: North America Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 30: North America Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 31: North America Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 32: North America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 33: North America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 34: North America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 35: North America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 36: North America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 37: North America Attractiveness by Drug Type, 2023 to 2033

Figure 38: North America Attractiveness by Route of Administration, 2023 to 2033

Figure 39: North America Attractiveness by Distribution Channel, 2023 to 2033

Figure 40: North America Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Value (US$ Million) by Drug Type, 2023 to 2033

Figure 42: Latin America Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 43: Latin America Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 44: Latin America Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 49: Latin America Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 50: Latin America Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 51: Latin America Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 52: Latin America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 53: Latin America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 54: Latin America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 55: Latin America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 56: Latin America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 57: Latin America Attractiveness by Drug Type, 2023 to 2033

Figure 58: Latin America Attractiveness by Route of Administration, 2023 to 2033

Figure 59: Latin America Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: Latin America Attractiveness by Country, 2023 to 2033

Figure 61: Europe Value (US$ Million) by Drug Type, 2023 to 2033

Figure 62: Europe Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 63: Europe Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 64: Europe Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 69: Europe Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 70: Europe Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 71: Europe Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 72: Europe Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 73: Europe Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 74: Europe Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 75: Europe Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 76: Europe Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 77: Europe Attractiveness by Drug Type, 2023 to 2033

Figure 78: Europe Attractiveness by Route of Administration, 2023 to 2033

Figure 79: Europe Attractiveness by Distribution Channel, 2023 to 2033

Figure 80: Europe Attractiveness by Country, 2023 to 2033

Figure 81: South Asia Value (US$ Million) by Drug Type, 2023 to 2033

Figure 82: South Asia Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 83: South Asia Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 84: South Asia Value (US$ Million) by Country, 2023 to 2033

Figure 85: South Asia Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: South Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: South Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: South Asia Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 89: South Asia Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 90: South Asia Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 91: South Asia Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 92: South Asia Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 93: South Asia Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 94: South Asia Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 95: South Asia Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 96: South Asia Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 97: South Asia Attractiveness by Drug Type, 2023 to 2033

Figure 98: South Asia Attractiveness by Route of Administration, 2023 to 2033

Figure 99: South Asia Attractiveness by Distribution Channel, 2023 to 2033

Figure 100: South Asia Attractiveness by Country, 2023 to 2033

Figure 101: East Asia Value (US$ Million) by Drug Type, 2023 to 2033

Figure 102: East Asia Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 103: East Asia Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 104: East Asia Value (US$ Million) by Country, 2023 to 2033

Figure 105: East Asia Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: East Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: East Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: East Asia Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 109: East Asia Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 110: East Asia Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 111: East Asia Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 112: East Asia Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 113: East Asia Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 114: East Asia Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 115: East Asia Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 116: East Asia Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 117: East Asia Attractiveness by Drug Type, 2023 to 2033

Figure 118: East Asia Attractiveness by Route of Administration, 2023 to 2033

Figure 119: East Asia Attractiveness by Distribution Channel, 2023 to 2033

Figure 120: East Asia Attractiveness by Country, 2023 to 2033

Figure 121: Oceania Value (US$ Million) by Drug Type, 2023 to 2033

Figure 122: Oceania Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 123: Oceania Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 124: Oceania Value (US$ Million) by Country, 2023 to 2033

Figure 125: Oceania Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: Oceania Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: Oceania Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: Oceania Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 129: Oceania Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 130: Oceania Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 131: Oceania Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 132: Oceania Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 133: Oceania Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 134: Oceania Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 135: Oceania Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 136: Oceania Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 137: Oceania Attractiveness by Drug Type, 2023 to 2033

Figure 138: Oceania Attractiveness by Route of Administration, 2023 to 2033

Figure 139: Oceania Attractiveness by Distribution Channel, 2023 to 2033

Figure 140: Oceania Attractiveness by Country, 2023 to 2033

Figure 141: MEA Value (US$ Million) by Drug Type, 2023 to 2033

Figure 142: MEA Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 143: MEA Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 144: MEA Value (US$ Million) by Country, 2023 to 2033

Figure 145: MEA Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 146: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 147: MEA Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 148: MEA Value (US$ Million) Analysis by Drug Type, 2018 to 2033

Figure 149: MEA Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 150: MEA Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 151: MEA Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 152: MEA Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 153: MEA Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 154: MEA Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 155: MEA Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 156: MEA Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 157: MEA Attractiveness by Drug Type, 2023 to 2033

Figure 158: MEA Attractiveness by Route of Administration, 2023 to 2033

Figure 159: MEA Attractiveness by Distribution Channel, 2023 to 2033

Figure 160: MEA Attractiveness by Country, 2023 to 2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Helicobacter Pylori Infections Treatment Market

Published : December 2022

Healthcare

Mosquito-borne infections Testing Market

Published : January 2019

Healthcare

Eye Infections Treatment Market

Published : February 2022

Google translate

Coxsackievirus Infections Treatment Market